Business Context and Reporting Period
Immunome, Inc. (IMNM), a Delaware corporation, filed this Form 8-K on December 16, 2025, to report a material event under Item 8.01 (Other Events). The company is an emerging growth company listed on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
This filing details a follow-on public offering rather than periodic financial performance metrics. Key transaction figures include:
- Shares Issued: 18,625,000 shares of Common Stock.
- Offering Price: $21.50 per share.
- Gross Proceeds: Approximately $400 million (before underwriting discounts and expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 2,793,750 additional shares.
- Expected Closing Date: December 18, 2025.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures; these are not applicable to this specific event-driven report.
Material Changes and Outlook
The primary material change is the execution of an underwriting agreement with Leerink Partners LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, and Guggenheim Securities, LLC. The offering is being made pursuant to a shelf registration statement (Form S-3) filed in February 2024.
Management commentary is limited to standard forward-looking statements regarding the expectation to close the offering and the inherent risks associated with market conditions and closing conditions. No specific operational guidance or strategic outlook beyond the capital raise is provided in this document.
Investor Verification Checklist
- Verify the final closing of the offering on or around December 18, 2025.
- Confirm whether the underwriters exercise the over-allotment option for the additional 2,793,750 shares.
- Review the final prospectus supplement for the exact amount of underwriting discounts and commissions to determine net proceeds.
- Check subsequent filings for the impact of this capital raise on the company's cash position and dilution metrics.